The authors studied the efficiency of Ingaron drug in the intensive phase of the complex treatment of newly diagnosed patients with destructive pulmonary bacterially proven tuberculosis, and the dynamics of clinical and immunological parameters. We examined 60 patients (the clinical trial of the drug was conducted in 30 newly diagnosed patients who received 500 000 IU Ingaron i/m, every other day for a month, in addition to standard therapy). Advantageously, the clinical form was infiltrative, which was diagnosed in 80% of patients in both groups (p> 0.05). After 2 months of intensive phase of treatment, the lung cavities closed in 23.3% of cases, and in 4 months, this figure was 50%. Abacillation occurred in 90% of patients taking Ingaron. A month later, normalization of blood count occurred in 70,0 ± 8,3% (21 of 30). Under the influence of immunomodulation there was noted an increase of CD4 count: up to 40,94 ± 3,11% (p <0.001 for the comparison with the same indicator before treatment). In the group of patients receiving additional Ingaron, CD4 count was 1.7 times greater than the initial level. The developed method of immunomodulating therapy is an essential complement to the anti-TB drugs from the standpoint of pathogenesis. The application of Ingaron in the complex treatment of patients with destructive pulmonary bacterially proven tuberculosis has shown its high efficiency in the intensive phase of chemotherapy, which significantly improves the quality of life of patients.